Compliance to consensus recommendations, surgeon's experience, and introduction of a quality assurance and management program influence on therapy of early-stage ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 19, Issue 4, 2009, Pages 787-793

  Kommoss, Stefan ^a   Harter, Philipp ^a   Traut, Alexander ^a   Strutas, Deivis ^a   Riegler, Nina ^a   Buhrmann, Christine ^a   Gomez, Ruth ^a   Bois, Andreas Du ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Chemotherapy; Compliance; Guidelines; Ovarian carcinoma; Physician; Staging

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PLATINUM; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; FEMALE; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OVARY CANCER; OVARY CARCINOMA; PATIENT CARE; PATIENT COMPLIANCE; PELVIS; PERFORMANCE; PERSONAL EXPERIENCE; PRIORITY JOURNAL; SURGEON; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; UTERUS CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; FEMALE; GUIDELINE ADHERENCE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; TAXOIDS; YOUNG ADULT;

EID: 67651021216     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a3a551     Document Type: Article

References (27)

1. du Bois A, Quinn M, Thigpen T, et al. 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16: viii7-viii12.
2. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer screening, treatment, and follow-up. JAMA. 1995;273: 491-497.
3. Kommission Ovar der Arbeitsgemeinschaft Gynäkologische Onkologie e. V. in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. sowie in der Deutschen Krebsgesellschaft e. V. Koordination: Barbara Schmalfeldt. Jacobus Pfisterer. Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren. München: Zuckschwerdt; 2007.
4. Trimbos JB, Bolis G. Guidelines for surgical staging of ovarian cancer. Obstet Gynecol Surv. 1994;49:814-816.
5. Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003;95:125-132.
6. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003; 95:113-125.
7. Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol. 2003;21:3488-3494.
8. Cress RD, O'Malley CD, Leiserowitz GS, et al. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol. 2003;21:1530-1535.
9. du Bois A, Rochon J, Lamparter C, et al. For the AGO Organkommission OVAR. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer. 2005;15:183-191.
10. Sijmons EA, van Lankveld MA, Witteveen PO, et al. Compliance to clinical guidelines for early-stage epithelial ovarian cancer in relation to patient outcome. Eur J Obstet Gynecol Reprod Biol. 2007;131:203-208.
11. Hébert-Croteau N, Brisson J, Latreille J, et al. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol. 2004;22:3685-3693.
12. Schrag D, Earle C, Xu F, et al. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst. 2006;98:163-171.
13. Aletti GD, Gostout BS, Podratz KC, et al. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol. 2006;100:33-37.
14. SPSS for Windows, Rel. 15.0.1. 2006. Chicago: SPSS Inc.
15. Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650-654.
16. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA. 1983;250:3072-3076.
17. Maggioni A, Benedetti Panici P, Dell'Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95:699-704.
18. Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:1238-1244.
19. Stier EA, Barakat RR, Curtin JP, et al. Laparotomy to complete staging of presumed early ovarian cancer. Obstet Gynecol. 1996;87:737-740.
20. Pfleiderer A. Is there any progress in the outcome of patients suffering from ovarian cancer? Treatment strategies since 1957. Gynecol Oncol. 2001;83:451-456.
21. Beckmann MW, Gitsch G, Emons G, et al. Qualification and education in gynecological oncology. Zentralbl Gynakol. 2006;128:1-4.
22. du Bois A, Rochon J, Lamparter C, et al. The Quality Assurance Program of the AGO Organkommission OVAR (QS-OVAR): Pattern of care and reality in Germany 2001. Zentralbl Gynakol. 2005;127:9-17.
23. Engelen MJ, Kos HE, Willemse PH, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106:589-598.
24. Kumpulainen S, Kuoppala T, Leminen A, et al. Surgical treatment of ovarian cancer in different hospital categories-a prospective nation-wide study in Finland. Eur J Cancer. 2006;42:388-395.
25. Eisenkop SM, Spirtos NM, Montag TW, et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47:203-209.
26. Carney ME, Lancaster JM, Ford C, et al. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol. 2002;84:36-42.
27. Castellucci P, Perrone AM, Picchio M, et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun. 2007; 28:589-595.